Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretical questions remain regarding their effectiveness, acceptability to patients, and economic sustainability. This trial aims to advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers. The investigators will pursue two specific aims: 1) comparing the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life and 2) comparing the short-term and long term return on investment of using goal directed and outcome-based financial incentives to promote smoking cessation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
1,058
Quitline offers community-based counseling session with a cessation counselor.
Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
Participants will receive financial incentives for bioconfirmed smoking cessation.
Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
David Geffen School of Medicine
Los Angeles, California, United States
NYU Langone Health
New York, New York, United States
Smoking abstinence assessed by self-report and biochemically verified by salivary cotinine
Assessed by self-report questionnaire, and biochemically verified by salivary cotinine
Time frame: 6 months
Use of evidence based treatment (e.g. counseling and smoking cessation medications) assessed by discharge prescriptions, Quitline records, receipts, letters and/or self-report
Assessed by discharge prescriptions, Quitline records, receipts, letters and/or self-report
Time frame: 2 months
Quality of life as measured by PROMIS-29 Profile v2.0
Assessed by phone interviews.
Time frame: 12 months
Short term return on investment of using financial incentives to promote smoking cessation (Cost analysis)
Cost analysis involving hospital utilization data, electronic health records and patient-reported healthcare utilization
Time frame: 12 months
Long term return on investment of using financial incentives to promote smoking cessation (Cost analysis)
Cost analysis involving hospital utilization data, electronic health records and patient-reported healthcare utilization
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.